Reported adverse effects in clinical trial studies:

- ARIA-edema (ARIA-E) (35%)*

- ARIA-hemosiderin deposition (ARIA-H) microhemorrhage (19%)*

- ARIA-H superficial siderosis (15%)*

- Headache (21%)

- Fall (15%)

- Diarrhea (9%)

- Confusion/delirium/altered mental status/disorientation (8%)

- Hypersensitivity (angioedema, urticaria) (<1%)

- Immunogenicity (<1%)

*Amyloid-related imaging abnormalities (ARIA)

Aducanumab can cause a small elevation in serum aminotransferase; however, there are no reports of liver injury.